• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Cell therapy for acute lung injury using lung derived trypsin resistant pluripotent cells

Research Project

Project/Area Number 25670665
Research Category

Grant-in-Aid for Challenging Exploratory Research

Allocation TypeMulti-year Fund
Research Field Anesthesiology
Research InstitutionTokyo Medical and Dental University

Principal Investigator

TANAKA Sonomi  東京医科歯科大学, 医学部附属病院, その他 (80644103)

Co-Investigator(Kenkyū-buntansha) 山本 寛人  東京医科歯科大学, 学内共同利用施設等, 助教 (80632174)
Project Period (FY) 2013-04-01 – 2016-03-31
Project Status Completed (Fiscal Year 2015)
Budget Amount *help
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords急性肺傷害 / エンドトキシン / 肺傷害モデル / トリプシン / 間葉系幹細胞 / 前駆細胞 / 蛋白分解酵素
Outline of Final Research Achievements

We studied the phenotype of the cells derived from rat lung tissue by trypsin treatment for 16 h, and we evaluated the efficacy of cell therapy using these cells for mouse acute lung injury model. The lung derived trypsin resistant cells had positivity for CD29 and CD90. Transcription of TIMP 1,4 and alpha-1 anti-trypsin were abundant. which might be related with tolerance to proteinases. When these cells were administered via nasal route to the lipopolysaccharide induced mice acute lung injury model, the activity of neutrophil elastase in the lung was reduced. These results suggested a possibility of these cells as a therapeutic approach to acute lung injury, but further study is needed to establish efficacy of this methodology.

Report

(4 results)
  • 2015 Annual Research Report   Final Research Report ( PDF )
  • 2014 Research-status Report
  • 2013 Research-status Report

URL: 

Published: 2014-07-25   Modified: 2019-07-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi